Dr. John A. Abraham

Daniel Lubelski is a fellowship-trained neurosurgeon with expertise in complex spine surgery and peripheral nerve surgery. He treats patients with spinal diseases and deformities, spine and nerve tumors, and brachial plexus injuries and other peripheral nerve injuries. Dr. Lubelski’s training in complex and robotic spine surgery, spinal oncology and peripheral nerve injuries allows him to comprehensively evaluate patients and develop custom treatment plans to address symptoms and improve patients’ quality of life. He prioritizes patient-centered care, effective communication and working in multidisciplinary collaboration to identify the best treatment. After obtaining his undergraduate degree at the City University of New York, Dr. Lubelski spent a year doing predoctoral research at the National Institutes of Health. He then obtained his medical degree from the Cleveland Clinic Lerner College of Medicine, and he performed stem cell tumor research as a Howard Hughes Medical Institute fellow. Dr. Lubelski went on to the Johns Hopkins University School of Medicine for a neurosurgery residency and an enfolded fellowship in peripheral nerve surgery. His postdoctoral training also included a fellowship in complex spine surgery and spinal oncology at Johns Hopkins, as well as a traveling fellowship with advanced training at the Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Dr. Lubelski is a prolific researcher who focuses on patient quality of life and on using big data to develop individualized prediction models to determine optimal treatments tailored to each person. He has authored more than 200 peer-reviewed papers and numerous textbook chapters, has lectured nationally and internationally, and serves as a reviewer for the top neurosurgical journals. Dr. Lubelski is rated as a Distinguished provider by MediFind in the treatment of Chordoma. His top areas of expertise are Spinal Tumor, Chordoma, Spinal Stenosis, Spinal Fusion, and Laminectomy.

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as an Elite provider by MediFind in the treatment of Chordoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, Fibrosarcoma, Osteosarcoma, and Salpingo-Oophorectomy.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Chordoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Squamous Cell Lung Carcinoma, and Non-Small Cell Lung Cancer (NSCLC).